Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Open Access
- 1 July 1993
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 178 (1) , 197-209
- https://doi.org/10.1084/jem.178.1.197
Abstract
The current vaccine against tuberculosis, Mycobacterium bovis strain bacille Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for the expression and delivery of protective recombinant antigens (Stover, C.K., V.F. de la Cruz, T.R. Fuerst, J.E. Burlein, L.A. Benson, L.T. Bennett, G.P. Bansal, J.F. Young, M.H. Lee, G.F. Hatfull et al. 1991. Nature [Lond]. 351:456; Jacobs, W.R., Jr., S.B. Snapper, L. Lugosi and B.R. Bloom. 1990. Curr. Top. Microbiol. Immunol. 155:153; Jacobs, W.R., M. Tuckman, and B.R. Bloom. 1987. Nature [Lond.]. 327:532); but as an attenuated intracellular bacterium residing in macrophages, BCG would seem to be best suited for eliciting cellular responses and not humoral responses. Since bacterial lipoproteins are often among the most immunogenic of bacterial antigens, we tested whether BCG expression of a target antigen as a membrane-associated lipoprotein could enhance the potential for a recombinant BCG vaccine to elicit high-titered protective antibody responses to target antigens. Immunization of mice with recombinant BCG vaccines expressing the outer surface protein A (OspA) antigen of Borrelia burgdorferi as a membrane-associated lipoprotein resulted in protective antibody responses that were 100-1,000-fold higher than responses elicited by immunization with recombinant BCG expressing OspA cytoplasmically or as a secreted fusion protein. Furthermore, these improved antibody responses were observed in heterogeneous mouse strains that vary in their immune responsiveness to OspA and sensitivity to BCG growth. Thus, expression of protective antigens as chimeric membrane-associated lipoproteins on recombinant BCG may result in the generation of new candidate vaccines against Lyme borreliosis and other human or veterinary diseases where humoral immunity is the protective response.Keywords
This publication has 34 references indexed in Scilit:
- Molecular cloning, expression, and DNA sequence analysis of the gene that encodes the 16-kilodalton outer membrane lipoprotein of Serpulina hyodysenteriaeInfection and Immunity, 1993
- Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigenJournal of Bacteriology, 1988
- Lysogeny and transformation in mycobacteria: stable expression of foreign genes.Proceedings of the National Academy of Sciences, 1988
- Identification and localization of integral membrane proteins of virulent Treponema pallidum subsp. pallidum by phase partitioning with the nonionic detergent triton X-114Infection and Immunity, 1988
- Expression of viral hemagglutinin on the surface ofE. coliJournal of Molecular Medicine, 1988
- Introduction of foreign DNA into mycobacteria using a shuttle phasmidNature, 1987
- Human T cell clones recognize two abundant Mycobacterium tuberculosis protein antigens expressed in Escherichia coli.The Journal of Immunology, 1987
- A Single Recombinant Plasmid Expressing Two Major Outer Surface Proteins of the Lyme Disease SpirocheteScience, 1985
- Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice.The Journal of Immunology, 1981
- The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen.The Journal of Experimental Medicine, 1975